IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
IceCure Medical has been granted an additional 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement, with the compliance period ending on November 9, 2026. The extension was granted because the company meets all other listing requirements, except for the bid price, and has expressed its intention to cure the deficiency, potentially through a reverse share split.
Key figures
- Minimum bid price
- $1.00
- Compliance period end
- November 9, 2026
- Consecutive days required
- 10
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.